Richard Pazdur will retire from the Food and Drug Administration only weeks after being named the head of its main drug review office.

A spokesperson for the FDA confirmed that Pazdur, the director of the Center for Drug Evaluation and Research, has submitted paperwork to retire at the end of December. The news was first reported by Stat News .

“We respect Dr. Pazdur’s decision to retire and honor his 26 years of distinguished service at the FDA,” the spokesperson wrote in an email to BioPharma Dive. “As the founding director of the Oncology Center of Excellence, he leaves a legacy of cross-center regulatory innovation that strengthened the agency and advanced care for countless patients. His leadership, vision, and dedication will continue to shape the FDA for years to come.”

Publish

See Full Page